Skip to main content

Immatics N.V.

IMTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001809196

In the last 90 days, Immatics N.V. insiders filed 1 open-market purchase and 0 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $1.01B in total; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $7.50M in total
1
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −2 vs. previous quarter
82
13F valueReported value at the end of Q2 2026
$1.01B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding IMTX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding IMTX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Immatics N.V. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 27, 2026 (view filing)4:00 PM ETAug 261 dayEdelman Joseph and 2 othersDirectorPPurchase+863.1K$8.69+$7.50M+8.3%11.2M after

Top 10 13F holders, Q2 2026

The largest institutional positions in Immatics N.V. at the end of Q2 2026; share changes are against Q1 2026.

See all 82 holders
Institutions holding IMTX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
T. Rowe Price Investment Management, Inc.22,365,046$226.6M0.15%+712,884+3.3%Added
RTW Investments, LP12,946,176$131.1M1.12%+76,836+0.6%Added
Suvretta Capital Management, LLC11,190,129$113.4M2.38%00.0%Unchanged
Perceptive Advisors LLC10,383,456$105.2M1.63%00.0%Unchanged
Baker Bros. Advisors LP9,508,565$96.3M0.48%−1,408,128−12.9%Reduced
Jefferies Financial Group Inc.6,506,802$65.9M0.61%+1,447,251+28.6%Added
Vestal Point Capital, LP6,175,000$62.6M1.46%00.0%Unchanged
Sofinnova Investments, Inc.3,669,346$37.2M1.99%+38,892+1.1%Added
Morgan Stanley2,186,494$22.1M0.00%+37,412+1.7%Added
Citadel Advisors LLC1,814,657$18.4M0.01%−37,306−2.0%Reduced